Research programme: fusion protein cancer therapeutics - Aida Pharmaceuticals

Drug Profile

Research programme: fusion protein cancer therapeutics - Aida Pharmaceuticals

Alternative Names: Vasostatin-Apo2L

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Aida Pharmaceuticals; Shanghai Qiaer Bio-Technology
  • Developer Shanghai Qiaer Bio-Technology
  • Class Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
  • 15 Mar 2007 Preclinical trials in Solid tumours in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top